Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer†

Author： Garnock-Jones Karly P. Keating Gillian M. Scott Lesley J.

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.24, Iss.3, 2010-06, pp. : 207-209

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Trastuzumab in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer

By Plosker Greg L. Keam Susan J.

BioDrugs, Vol. 20, Iss. 4, 2006-01 ,pp. : 259-262

Adis International

Access to resources Recommend Favorite

HER-2-Positive Breast Cancer: Hope Beyond Trastuzumab

By Bartsch Rupert Wenzel Catharina Zielinski Christoph C. Steger Guenther G.

BioDrugs, Vol. 21, Iss. 2, 2007-01 ,pp. : 69-77

Adis International

Access to resources Recommend Favorite

Trastuzumab in HER2-Positive Metastatic Gastric Cancer†: Profile Report

By Croxtall Jamie D. McKeage Kate

BioDrugs, Vol. 25, Iss. 4, 2011-08 ,pp. : 257-259

Adis International

Access to resources Recommend Favorite

Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer†: Profile Report

By Curran Monique P.

BioDrugs, Vol. 25, Iss. 1, 2011-02 ,pp. : 53-54

Adis International

Access to resources Recommend Favorite

Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies

By Nedergaard Mette K. Hedegaard Chris J. Poulsen Hans S.

BioDrugs, Vol. 26, Iss. 2, 2012-04 ,pp. : 83-99

Adis International

Access to resources Recommend Favorite